Highlights Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:31:47 11/07/2025 BST			5-day change	1st Jan Change
256.80 ^CHF	-2.36%		-1.23%	+0.51%

07-10	ROCHE HOLDINGS AG : Buy rating from UBS	ZD
07-09	Swiss Market Index Closes Higher; SGS Shares Down	MT

Highlights

Roche's Lebanese Unit Renews Healthcare Collaboration with Universities	07-03	MT
Berenberg Cuts Zealand Pharma's Price Target Amid Increased Competition	07-01	MT
Rakovina Therapeutics Inc. Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025	06-30	CI
Roche Diagnostics, Egypt's UPA Partner to Advance Green Procurement in Healthcare	06-26	MT
Lineage Cell Therapeutics, Inc. Announces 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025	06-23	CI
Roche: positive Phase I/II data in hemophilia A	06-23	CF
MAIA Biotechnology, Inc. Announces Master Clinical Supply Agreement with Roche for Hard-To-Treat Cancer Therapies	06-18	CI
Sarepta shares crash as second patient dies after receiving its gene therapy	06-16	RE
AbbVie says blood cancer drug fails late-stage trial	06-16	RE
North American Morning Briefing : Stock Futures Rise As Israel-Iran Conflict Enters Fourth Day	06-16	DJ
Roche: moving towards phase 3 in Parkinson's disease	06-16	CF
Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease	06-16	CI
US FDA approves Nuvation Bio's rare lung cancer drug	06-11	RE
Pharma Mar's Supplemental New Drug Application for Lung Cancer Drug Combo Gets US FDA Priority Review	06-10	MT
Roche's Middle Eastern Arm Launches Sustainable Healthcare Lab Certification Initiative	06-10	MT
Roche's Evrysdi Tablet Gets EU Clearance for Spinal Muscular Atrophy Treatment	06-04	MT
EU Approves New Tablet Formulation for Roche's Spinal Muscular Atrophy Treatment	06-04	MT
EU Approves Roche's Evrysdi Tablet For Spinal Muscular Atrophy	06-04	MT
Pharmamar Announces Positive Results from the Phase 3Imforte Study of Zepzelca®? (Lurbinectedin) in Combination with Atezolizumab	06-03	CI
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer	05-31	CI
WRAPUP 5-Trump officials downplay court ruling that blocked sweeping tariffs	05-29	RE
EU Panel Backs Roche's Marketing Authorization Application for Breast Cancer Drug	05-23	MT
EMA's CHMP Says Positive Opinion Was Adopted For Blenrep - Website	05-23	RE
Roche: collaboration with Broad Clinical Labs	05-23	CF
Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals	05-23	RE